Amgen Loses Ruling Over Teva, Amneal’s Versions of Sensipar (2)

Amgen Inc. lost a court ruling, and pledged to appeal, as it tries to block generic versions of its kidney disease drug Sensipar.

Three generic-drug makers — Amneal Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd.’s Watson, and Piramal Enterprises Ltd.’s health-care unit — don’t infringe an Amgen patent that expires in 2026, U.S. District Judge Mitchell S. Goldberg in Wilmington, Del., ruled July 27.

A fourth generic-drug maker, Cadila Healthcare Ltd.’s Zydus, does infringe the patent for a fast-dissolving version of the drug, but the judge said the validity of the patent is still at issue. Zydus is the only one ...